CNBX Pharmaceuticals (CNBX) Debt to Equity (2016 - 2024)
CNBX Pharmaceuticals (CNBX) has disclosed Debt to Equity for 7 consecutive years, with -$0.52 as the latest value for Q3 2024.
- For the quarter ending Q3 2024, Debt to Equity rose 21.59% year-over-year to -$0.52, compared with a TTM value of -$0.52 through Aug 2024, up 21.59%, and an annual FY2024 reading of -$0.52, up 21.59% over the prior year.
- Debt to Equity was -$0.52 for Q3 2024 at CNBX Pharmaceuticals, up from -$0.67 in the prior quarter.
- Across five years, Debt to Equity topped out at $1.33 in Q4 2021 and bottomed at -$2.04 in Q1 2022.
- Average Debt to Equity over 4 years is -$0.28, with a median of -$0.59 recorded in 2023.
- Peak annual rise in Debt to Equity hit 123.16% in 2022, while the deepest fall reached 1107.8% in 2022.
- Year by year, Debt to Equity stood at $1.33 in 2021, then crashed by 167.08% to -$0.89 in 2022, then rose by 25.42% to -$0.67 in 2023, then grew by 21.59% to -$0.52 in 2024.
- Business Quant data shows Debt to Equity for CNBX at -$0.52 in Q3 2024, -$0.67 in Q3 2023, and -$0.7 in Q2 2023.